← Leaderboards
Mark E Sherman
Mayo Clinic Jacksonville
$5,733,205
Attributed
$11,027,724
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,027,724 · 9
By mechanism
R01$8,805,782 · 3
P50$1,703,986 · 4
R21$388,331 · 1
P30$129,625 · 1
Top collaborators
- Amy C Degnim14 shared
- Derek C Radisky11 shared
- Kathryn Jean Ruddy4 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Kathryn Jean Ruddy$3,623,191
- Brian M Necela$185,419
Others in their field
Top investigators on “Benign”
- Timothy P Lodge · Gordon Research Conferences$35,514,008
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$34,768,427
- Karen I Goldberg · University Of Washington$21,992,188
- Nicholas Hud · Emory University$20,320,616
- Robert J Hamers · University Of Wisconsin-Madison$19,800,000
- Tracy A Glauser · Children'S Hospital Med Ctr (Cincinnati)$19,517,752
Research focus
BenignBiopsyClinicMalignant Breast NeoplasmBiological MarkersBreast DiseasesWomanMalignant NeoplasmsPreventionCohortNano-StringImmunohistochemistrySamplingBreast Cancer Risk FactorRisk FactorsEpithelial CellsLobuleInnovationPathway InteractionsPathologyLinkFutureCellsMammary Gland Parenchyma
Grant awards (31)
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$650,300
R01 · FY2025 · CA · contact PI
Biospecimen Core$267,960
P50 · FY2025 · CA · contact PI
Cancer Risk Assessment, Early Detection, and Interception Research Program$129,625
P30 · FY2025 · CA · contact PI
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$617,447
R01 · FY2024 · CA · contact PI
Involution-based biomarkers of breast cancer risk$473,716
R01 · FY2024 · CA
Biospecimen Core$317,989
P50 · FY2024 · CA · contact PI
Biospecimens and Patient Registry$170,572
P50 · FY2024 · CA · contact PI
Involution-based biomarkers of breast cancer risk$141,218
R01 · FY2024 · CA
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$653,945
R01 · FY2023 · CA · contact PI
Involution-based biomarkers of breast cancer risk$486,563
R01 · FY2023 · CA
Biospecimen Core$287,748
P50 · FY2023 · CA · contact PI
Biospecimens and Patient Registry$186,623
P50 · FY2023 · CA · contact PI
Involution-based biomarkers of breast cancer risk$148,650
R01 · FY2023 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$639,236
R01 · FY2022 · CA · contact PI
Targeted Prevention of Postpartum-Related Breast Cancer (PRBC)$627,061
R01 · FY2022 · CA · contact PI
Involution-based biomarkers of breast cancer risk$488,556
R01 · FY2022 · CA
Biospecimen Core$287,771
P50 · FY2022 · CA · contact PI
Biospecimens and Patient Registry$185,323
P50 · FY2022 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$637,416
R01 · FY2021 · CA · contact PI
Involution-based biomarkers of breast cancer risk$507,487
R01 · FY2021 · CA
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$102,875
R01 · FY2021 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$721,306
R01 · FY2020 · CA · contact PI
Involution-based biomarkers of breast cancer risk$554,827
R01 · FY2020 · CA
Novel Multiplex Biomarker Discovery Methods To Predict Breast Cancer Risk After A Benign Biopsy$204,990
R21 · FY2020 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$619,727
R01 · FY2019 · CA · contact PI
Novel Multiplex Biomarker Discovery Methods To Predict Breast Cancer Risk After A Benign Biopsy$183,341
R21 · FY2019 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$95,085
R01 · FY2019 · CA · contact PI
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy$640,367
R01 · FY2018 · CA · contact PI
CORE--HUMAN SPECIMEN RESOURCE AND DATABASE$0
P50 · FY2002 · CA
CORE--HUMAN SPECIMEN RESOURCE AND DATABASE$0
P50 · FY2001 · CA
CORE--HUMAN SPECIMEN RESOURCE AND DATABASE$0
P50 · FY2000 · CA